Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pfizer naming Deirdre Gillane .
Filed returns
24
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Jan–Apr 2026 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 16 | On lobbying.ie |
| May–Aug 2025 | Pfizer | Trade | Raise concern about the impact of potential tariffs and related geo-political issues related to the pharmaceutical industry and pricing of medicines globally (Public policy or programme) | 11 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Trade | Raise concern about the impact of potential tariffs on pharmaceutical manufacturing and supply of medicines to patients globally (Public policy or programme) | 11 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 7 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | Economic Development and Industry | Life Science Strategy and Industrial Policy (Public policy or programme) | 8 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 15 | On lobbying.ie |
| May–Aug 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 14 | On lobbying.ie |
| Sep–Dec 2023 | Pfizer | Health | Ireland's medicine reimbursement system and Budget funding for new medicines (Matters involving public funds) | 9 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | Economic Development and Industry | Pfizer recent 1.2 billion euro investment in Ireland operations creating 400-500 jobs (Public policy or programme) | 13 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | EU Affairs | EC HERA contract in relation to Pfizer COVID-19 vaccine (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | EU Affairs | EC HERA contract in relation to Pfizer COVID-19 vaccine (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Energy and Natural Resources | Potential energy shortages (Public policy or programme) | 7 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Budgetary matters | Budget 2023 (Public policy or programme) | 8 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Economic Development and Industry | COVID-19 Trips waiver - vaccines and therapeutics (Public policy or programme) | 7 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Budgetary matters | Budget 2023 (Public policy or programme) | 9 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Health | COVID-19 vaccination programme (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2022 | Pfizer | Health | Update on Pfizer COVID 19 antiviral treatment and processes in ensuring availability of the treatment in Ireland (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Health | COVID-19 vaccination programme (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Health | Pfizer has an investigational COVID-19 treatment, a protease inhibitor which subject to clinical trials and regulatory approvals could play a complementary role to vaccination in helping to manage COVID-19 (Matters involving public funds) | 5 | On lobbying.ie |
| May–Aug 2021 | Pfizer | Health | Supply of Pfizer COVID-19 vaccine including Ireland volumes; expansion of manufacturing capacity to include Grange Castle site and Pfizer colleague vaccination programme (Public policy or programme) | 8 | On lobbying.ie |
| May–Aug 2021 | Pfizer | Economic Development and Industry | Globally, debate is underway in relation to a COVID-19 vaccines IP waiver (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | Economic Development and Industry | Highlight the importance of pharmaceutical manufacturing activity being deemed essential activity to ensure the continued operation of Pfizer manufacturing sites wh (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | EU Affairs | Highlight Pfizer concerns re proposed EU vaccine export restrictions and how this could impact Pfizer's ability to manufacture the COVID 19 vaccine and provide supply globally (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | Health | Updates in relation to Pfizer COVID 19 vaccine including global production, Ireland volumes and company colleague vaccination programme (Matters involving public funds) | 10 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 9 | 37.5% | |
| EU Affairs | 5 | 20.8% | |
| Economic Development and Industry | 5 | 20.8% | |
| Budgetary matters | 2 | 8.3% | |
| Trade | 2 | 8.3% | |
| Energy and Natural Resources | 1 | 4.2% |